Elk Grove student tests positive for tuberculosis, contact tracing underway
The Monterey Trail High School student's positive case was reported on Thursday, but Sacramento County Public Health said the tuberculosis exposure happened between April 11 and July 17.
Health officials are now reaching out to students, teachers and staff who may have been exposed.
"While the risk of infection is low, it is recommended that individuals who receive an exposure notification letter be tested," said Dr. Olivia Kasirye, Sacramento County's Health Officer, in a statement.
Exactly how the student contracted tuberculosis is not clear. The student is expected to fully recover, health officials say.
California saw 2,100 reported cases of tuberculosis in 2024, according to California Department of Public Health numbers, with Sacramento County accounting for 110 of those cases.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
9 minutes ago
- News24
5 acne triggers hiding in plain sight
These five everyday items you touch (like hats, headphones and makeup brushes) might be sabotaging your skin. Here's how to keep them clean and your breakouts at bay.
Digital Trends
an hour ago
- Digital Trends
The 2026 Apple Watch could get upgrades that I've been waiting for years
In just over a month, Apple will introduce the world to a fresh portfolio of iPhones. Rumors have focused on a camera-centric design overhaul for the 'Pro' flagships and a whole new ultra-slim sibling that will adopt the 'Air' branding. It sounds like this year's Apple Watch may not be a showstopper of the Fall launch event, but its successor might turn out to be one that I've been waiting for ages. According to supply chain outlet DigiTimes, the purported Apple Watch Series 12 set to arrive in 2026 could be a massive overhaul, both inside and outside. 'The high-end Apple Watch model launching in 2026 is expected to undergo substantial upgrades and redesigns centered around enhanced sensing capabilities,' says the report. Recommended Videos Citing multiple supply chain sources, the report mentions three key areas of improvement for the 2026 Apple Watch related to battery, biosensing, and aesthetics. Starting with the sensors, Apple reportedly plans to double the number of sensors on its smartwatch, going from four to eight. A big leap for on-wrist biosensing Supplied by TASC, the report notes that the sensors will be arranged in a ring-like shape on the underside, protected by a transparent glass cover. Aside from opening the doors for new health sensing capabilities, the new sensors will reportedly help improve battery efficiency, as well. Now, let's talk about the next-gen biosensing chops. Rumors suggest that blood pressure sensing will finally land on the Apple Watch this year, or next. Apple is most likely relying on the same light-based technique for assessing the blood pressure that we've already seen on Samsung's Galaxy smartwatches. This approach relies on calibration with a medical-grade sensor, while Huawei has developed a micropump system for its smartwatches that works standalone. Older reports claim that the Apple Watch won't tell absolute systolic/diastolic blood pressure values, but will simply warn users about any abnormal spikes or drops. Another promising wellness feature is non-invasive blood glucose level analysis. Apple has been working on the tech stack for years, but due to regulatory concerns and technical challenges, it hasn't served it aboard an Apple Watch, yet. The underlying tech, however, has been in development in other labs for years. In 2022, experts at Georgia's Kennesaw State University reported the development of a noninvasive system of blood glucose level measurement device called GlucoCheck that works in tandem with a mobile application. A year later, Movano revealed an AI-powered needle-free wearable that lets users check real-time glucose data. Michael Leabman, the company's CEO and founder, told Digital Trends that their smartwatch relies on an onboard radio frequency-powered sensor for the job. So far, no mainstream smartwatch brand has delivered on glucose analysis tech, and if Apple manages to pull it off, it would mark yet another huge leap for the company. What else is on the table? The DigiTimes report also hints at big gains in the battery life department. It notes that on the Apple Series 12, 'power efficiency will improve significantly.' I am more excited about this upgrade, which is supposedly made possible by shifting to a next-gen sensor hub. Over the past couple of years, smartwatches running Google's Wear OS software have made big strides in the battery life department. The OnePlus Watch 2 and its successor, owing to their unique dual-OS approach, can easily go past two days without losing any of their functional charm. Samsung's current generation Galaxy Watch 8 series smartwatches also last longer, and in my tests, they comfortably got past a day. With battery saving tools applied, while disabling always-on display and frugal background activity, I got a per-charge mileage close to a couple of days. Apple's smartwatches rarely go past a full day on a single charge. Finally, the 2026 Apple Watch is also said to be in line for a design makeover, a year ahead of a similar treatment planned for the anniversary edition iPhone. The report only mentions 'a significant redesign,' but doesn't go into details about any minute details. Since its market arrival, the Apple Watch has retained the same fundamental design, with the only notable changes being a slimming down of the chassis and the switch to a curved display. Apple is reportedly planning to add cameras to its smartwatch, but there is little clarity whether the 2026 Apple Watch will be the first to get it.
Fox News
3 hours ago
- Fox News
Cancer vaccine shows promise in preventing recurrence of pancreatic, colorectal tumors
An experimental cancer vaccine has shown promise in keeping certain cancers from coming back. In a phase 1 clinical trial led in part by the UCLA Health Jonsson Comprehensive Cancer Center, researchers tested the vaccine (ELI-002 2P) with 25 patients who had been treated for pancreatic and colorectal cancer. The patients had all undergone surgery to remove tumors and showed "signs of minimal residual disease" or traces of DNA, putting them at a high risk of recurrence, according to a UCLA press release. More than 80% of pancreatic cancer patients experience recurrence of the disease after surgery, research shows — and for 40% to 50%, this happens within the first year. For colorectal cancer, the recurrence rate is between 30% and 50% and is most likely to occur within the first two years after surgery. Mutations in the KRAS gene are responsible for half of colorectal cancers and more than 90% of pancreatic cancers. The vaccine, which targets those mutations, was given via a series of injections to activate an immune response in the lymph nodes. A majority (21 out of 25) of the patients generated "KRAS-specific T cells," which indicates a stronger immune response. The ones with higher T-cell responses showed a longer relapse-free survival compared to those with lower responses, the researchers found. For three colorectal cancer patients and three pancreatic cancer patients, the vaccine appeared to remove all disease biomarkers. Among the patients who showed the strongest immune response, a majority were still cancer-free nearly 20 months after receiving the vaccine. The findings were published in Nature Medicine. "This is an exciting advance for patients with KRAS-driven cancers, particularly pancreatic cancer, where recurrence after standard treatment is almost a given and effective therapies are limited," said first author of the study, Zev Wainberg, M.D., professor of medicine at the David Geffen School of Medicine at UCLA and researcher in the UCLA Health Jonsson Comprehensive Cancer Center, in the release. "We observed that patients who developed strong immune responses to the vaccine remained disease-free and survived for much longer than expected." "The new cancer vaccine from UCLA is very promising as a major tool against these cancers." In another finding, 67% of the patients in the trial showed immune responses to "additional tumor-associated mutations," indicating that the vaccine could be used to suppress "broader anti-tumor activity." One of the benefits of ELI-002 2P, according to the researchers, is that it's considered "off-the-shelf," which means it's a mass-produced, standardized vaccine that doesn't have to be personalized for each individual patient. "This study shows that the ELI-002 2P vaccine can safely and effectively train the immune system to recognize and fight cancer-driving mutations," Wainberg said. "It offers a promising approach to generating precise and durable immune responses without the complexity or cost of fully personalized vaccines." The team has already finished enrolling participants for a phase 2 study that will test ELI-002 7P, the next iteration of the vaccine that will target a "broader set" of KRAS mutations, the release stated. The study was sponsored and funded by Elicio Therapeutics, the Massachusetts company that developed the vaccine. It was conducted in conjunction with the MD Anderson Cancer Center and the Memorial Sloan Kettering Cancer Center. Dr. Marc Siegel, Fox News senior medical analyst, was not involved in the study but commented that targeted therapies are becoming increasingly important tools in the fight against cancer. "Solid tumors, especially pancreatic, can be difficult to treat because they are not as mutagenic (capable of inducing or causing mutations) as hematological malignancies (blood cancers) or melanoma, for example, so they don't have as many ready targets for immunotherapy," he told Fox News Digital. For more Health articles, visit "The new cancer vaccine from UCLA is very promising as a major tool against these cancers, as it 'programs' the immune system to target these mutations and has been shown in the NATURE study to elicit a strong clinical response."
